PRISMA-ScR Protocol: Psilocybin therapy for demoralization in patients with terminal illness, a scoping review

Abstract

A scoping review to conceptualise and map the breadth of studies concerning psilocybin-assisted psychotherapy for existential distress and demoralization for patients with life-limiting illness. Psilocybin has demonstrated effective and lasting effects, up to 4.5 years, in clinical studies (Agin-Liebes et al., 2020) to treat existential distress in patients with cancer and is relatively safe in controlled settings even though it is a powerful drug. Psilocybin can be accessed by application to health authorities in Australia, Canada, Switzerland and couple of states in the USA (Oregon and Colorado) to treat existential distress and treatment resistant depression but is not widely available.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

Keywords